Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Payables (2022 - 2025)

Mangoceuticals' Payables history spans 4 years, with the latest figure at $416682.0 for Q4 2025.

  • On a quarterly basis, Payables fell 57.8% to $416682.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $416682.0, a 57.8% decrease, with the full-year FY2025 number at $416682.0, down 57.8% from a year prior.
  • Payables hit $416682.0 in Q4 2025 for Mangoceuticals, down from $626964.0 in the prior quarter.
  • Over the last five years, Payables for MGRX hit a ceiling of $1.3 million in Q2 2025 and a floor of $30796.0 in Q1 2023.
  • Historically, Payables has averaged $577669.0 across 4 years, with a median of $626964.0 in 2025.
  • Biggest five-year swings in Payables: soared 3483.08% in 2024 and later plummeted 57.8% in 2025.
  • Tracing MGRX's Payables over 4 years: stood at $111935.0 in 2022, then grew by 25.76% to $140765.0 in 2023, then surged by 601.52% to $987501.0 in 2024, then plummeted by 57.8% to $416682.0 in 2025.
  • Business Quant data shows Payables for MGRX at $416682.0 in Q4 2025, $626964.0 in Q3 2025, and $1.3 million in Q2 2025.